Cathie Wood’s ARK sells Eli Lilly stock, buys Tempus AI and Coinbase
ARK ETFs sold 17,626 shares of Eli Lilly (LLY) for $24.2M and bought shares in Tempus AI (TEM) for $12M, Coinbase (COIN) for $6.3M, Circle (CRCL) for $6M, Pacific Biosciences (PACB) for $1.4M, and Robinhood (HOOD) for $1.3M. They also sold shares in Bullish (BLSH) for $6.8M and CareDx (CDNA) for $3.6M.
How this was made
The 30-second read
Why it matters
The net effect is a reallocation from pharma to AI‑focused and crypto‑related assets.
Market read
Provides actionable data for traders monitoring fund flows and sector rotation.
What to watch
Potential upcoming earnings or clinical data could drive price moves independent of ARK trades.
Background
ARK's daily trade disclosures provide insight into its evolving investment thesis across sectors.
Ticker impact
ARK sold 17,626 shares of Eli Lilly, reducing its stake.
likely downward pressure as the market prices in the sell.
Large sell order from a high‑profile fund can push the stock lower in the short term.
ARK bought 154,521 shares of Tempus AI across its ARKK and ARKG ETFs.
likely upward pressure as the market absorbs the purchase.
Significant purchase by a well‑known growth fund may boost sentiment.
ARK added 39,418 shares of Coinbase to its ARKK, ARKW and ARKF ETFs.
potential modest upside as the fund signals confidence in the exchange.
Fund buying can offset recent crypto volatility, but broader market sentiment remains mixed.
ARK purchased 74,894 shares of Circle Internet Group.
likely slight upward pressure.
Circle’s exposure to stablecoins may benefit from ARK’s allocation.
ARK bought 480,274 shares of Pacific Biosciences.
potential modest upside.
Large share purchase signals confidence in genomics sector.
ARK increased its stake in Robinhood with a purchase of 13,757 shares.
likely upward pressure.
Continued buying by ARK may reinforce bullish sentiment.
ARK sold 238,373 shares of Bullish, exiting the position.
likely downward pressure.
Large sell from a prominent fund can depress the stock.
ARK reduced its holding in CareDx, selling 50,859 shares.
potential downside as the market absorbs the sell.
Significant reduction by ARK may signal concerns about the biotech.
Market effects
Highlights ARK's shifting focus within biotech and AI‑driven healthcare.
Primarily U.S. equity market; no direct regional effect.
Limited to investors tracking ARK's portfolio allocations.
Counterpoint
Some may view ARK's exits as a signal to short the sold stocks.
Key entities
- PersonCathie Wood
Founder of ARK Invest, whose fund actions influence market sentiment.
